Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Dr Seth Lederman tells Proactive the clinical-stage biopharmaceutical company has revealed preliminary results of its COVID-19 vaccine candidate.
Lederman says its vaccine candidate TNX-1800 had undetectable SARS-CoV-2 within animal models, within upper and lower airways 6 days after injected with SARS-CoV-2.